The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
NCT00401245
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Generally healthy, postmenopausal woman who seeks treatment for hot flushes.
- Meets 1 of the following: At least 12 months of spontaneous amenorrhea; At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL; At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy). Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/mL.
- History of a seizure disorder other than a single childhood febrile seizure.
- History or presence of clinically important hepatic or renal disease or other medical
disease.
- Presence or recent history of major depressive disorder, bipolar disorder, psychotic
disorder, or generalized anxiety disorder requiring therapy.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Montgomery, Alabama
- Peoria, Arizona
- San Diego, California
- Stanford, California
- Colorado Springs, Colorado
- Newark, Delaware
- Aventura, Florida
- Ft. Myers, Florida
- Inverness, Florida
- Miami, Florida
- New Port Richey, Florida
- Ocala, Florida
- Orange City, Florida
- Pinellas Park, Florida
- Tampa, Florida
- West Palm Beach, Florida
- West Venice, Florida
- Atlanta, Georgia
- Savannah, Georgia
- Newburgh, Indiana
- Lexington, Kentucky
- Shreveport, Louisiana
- Portland, Maine
- Chaska, Minnesota
- Jackson, Mississippi
- St. Louis, Missouri
- Billings, Montana
- Las Vegas, Nevada
- Reno, Nevada
- Albuquerque, New Mexico
- Albuquerque, New Mexico
- Winston-Salem, North Carolina
- Canton, Ohio
- Cincinnati, Ohio
- Cincinnati, Ohio
- Portland, Oregon
- Erie, Pennsylvania
- Wexford, Pennsylvania
- Greenville, South Carolina
- San Antonio, Texas
- Norfolk, Virginia
- Birmingham, Alabama
- Mobile, Alabama
- Montgomery, Alabama
- Glendale, Arizona
- Peoria, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Jonesboro, Arkansas
- Little Rock, Arkansas
- Little Rock, Arkansas
- San Diego, California
- San Diego, California
- San Diego, California
- Vista, California
- Walnut Creek, California
- Colorado Springs, Colorado
- Denver, Colorado
- Englewood, Colorado
- Longmont, Colorado
- New London, Connecticut
- Newark, Delaware
- Brooksville, Florida
- Clearwater, Florida
- Clearwater, Florida
- Daytona Beach, Florida
- Fort Myers, Florida
- Gainesville, Florida
- Lake Worth, Florida
- New Port Richey, Florida
- Palm Harbor, Florida
- Pembroke Pines, Florida
- South Miami, Florida
- Tampa, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Decatur, Georgia
- Decatur, Georgia
- Savannah, Georgia
- Boise, Idaho
- Idaho Falls, Idaho
- Indianapolis, Indiana
- Indianapolis, Indiana
- South Bend, Indiana
- Overland Park, Kansas
- Lexington, Kentucky
- Louisville, Kentucky
- New Orleans, Louisiana
- Scarborough, Maine
- Ann Arbor, Michigan
- Brooklyn Center, Minnesota
- Creve Coeur, Missouri
- Billings, Montana
- Billings, Montana
- Lincoln, Nebraska
- Las Vegas, Nevada
- Las Vegas, Nevada
- Reno, Nevada
- Lebanon, New Hampshire
- New Brunswick, New Jersey
- Albuquerque, New Mexico
- New York, New York
- Winston-Salem, North Carolina
- Bismarck, North Dakota
- Fargo, North Dakota
- Jamestown, North Dakota
- Akron, Ohio
- Cincinnati, Ohio
- Cleveland, Ohio
- Englewood, Ohio
- Oklahoma City, Oklahoma
- Eugene, Oregon
- Medford, Oregon
- Erie, Pennsylvania
- Erie, Pennsylvania
- Jenkintown, Pennsylvania
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Wexford, Pennsylvania
- Warwick, Rhode Island
- Greer, South Carolina
- Hilton Head Island, South Carolina
- Sioux Falls, South Dakota
- Sioux Falls, South Dakota
- Watertown, South Dakota
- Chattanooga, Tennessee
- Knoxville, Tennessee
- Nashville, Tennessee
- Dallas, Texas
- Houston, Texas
- Midland, Texas
- Plano, Texas
- San Antonio, Texas
- Waco, Texas
- Salt Lake City, Utah
- Sandy, Utah
- Burlington, Vermont
- Norfolk, Virginia
- Norfolk, Virginia
- Richmond, Virginia
- Seattle, Washington
- Menomonee Falls, Wisconsin
- Calgary, Alberta
- Coquitlam, British Columbia
- Surrey, British Columbia
- Winnipeg, Manitoba
- Antigonish, Nova Scotia
- Corunna, Ontario
- Ottawa, Ontario
- Sarnia, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Gatineau, Quebec
- L'Ancienne-Lorette, Quebec
- Pointe Claire, Quebec
- Saint-Janvier, Quebec
- Shawinigan, Quebec
- Sherbrooke, Quebec
- St-Romuald, Quebec
- Quebec,
- Tucson, Arizona
- Tucson, Arizona
- Beverly Hills, California
- Encinitas, California
- Foothill Ranch, California
- San Diego, California
- San Diego, California
- Upland, California
- Denver, Colorado
- Longmont, Colorado
- Clearwater, Florida
- Crystal River, Florida
- Deland, Florida
- Gainesville, Florida
- Lake Worth, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Palm Harbor, Florida
- Tampa, Florida
- Idaho Falls, Idaho
- Champaign, Illinois
- Chicago, Illinois
- South Bend, Indiana
- Lexington, Kentucky
- Louisville, Kentucky
- Metairie, Louisiana
- Metairie, Louisiana
- Canton, Michigan
- Ypsilanti, Michigan
- Billings, Montana
- Omaha, Nebraska
- Las Vegas, Nevada
- Lebanon, New Hampshire
- New Brunswick, New Jersey
- Albuquerque, New Mexico
- Albuquerque, New Mexico
- New York, New York
- Chapel Hill, North Carolina
- Charlotte, North Carolina
- Winston-Salem, North Carolina
- Winston-Salem, North Carolina
- Bismarck, North Dakota
- Fargo, North Dakota
- Cleveland, Ohio
- Eugene, Oregon
- Pittsburgh, Pennsylvania
- Watertown, South Dakota
- Carrollton, Texas
- Houston, Texas
- Hurst, Texas
- Midland, Texas
- Norfolk, Virginia
- Norfolk, Virginia
- Seattle, Washington
- Calgary, Alberta
- Coquitlam, British Columbia
- Langley, British Columbia
- Surrey, British Columbia
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- St. John's, Newfoundland and Labrador
- Newmarket, Ontario
- Sarnia, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Pointe Claire, Quebec
- Shawinigan, Quebec
- Sherbrooke, Quebec
- St-Romuald, Quebec
- Quebec,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms | |||
Official Title ICMJE | The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study | |||
Brief Summary | Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is a nonhormonal option for the treatment of Vasomotor Symptoms (VMS) associated with menopause. Nausea is the most common adverse event that is observed in clinical studies and is the main reason for discontinuation during the first week of therapy. Other adverse events (headache, nausea, and dizziness) associated with DVS SR have been noted to occur when subjects abruptly discontinue the medication. The purpose of this study is to evaluate several titration and tapering regimens of DVS SR to ensure a better tolerability profile at the start and completion of treatment. In addition, this study will provide a long posttreatment follow-up to assess any symptoms after treatment is discontinued. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Vasomotor Symptoms | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 500 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | January 2008 | |||
Actual Primary Completion Date | January 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Canada, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00401245 | |||
Other Study ID Numbers ICMJE | 3151A2-405 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | October 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |